On the evening of February 8th, on issues related to the new coronavirus pneumonia clinical trial of the drug Remdesivir, Gilead said in a statement that the company expects the lead research unit for clinical trials to release more details in the near future. At the same time, given the urgency of the current situation, Gilead has accelerated production and increased supply.
Redcivir is a broad-spectrum antiviral drug under research that has not yet been approved in any country around the world. Redciewe has demonstrated the activity of MERS and SARS virus pathogens in in vitro and in vitro animal models, which are also coronaviruses and are structurally similar to the new coronavirus (2019-nCoV). Limited preclinical data from MERS and SARS indicate that Redcivir may have potential lynoviruses (2019-nCoV).
Currently, Gilead has reached an agreement with the Chinese health authorities to support two clinical trials of people infected with the new coronavirus (2019-nCoV) to determine the safety and efficacy of Redcyvir as a potential treatment for coronavirus. One study assessed the effectiveness of Redcivir in patients diagnosed with a new coronavirus (2019-nCoV) that had been hospitalized but did not exhibit significant clinical symptoms, such as the need for additional oxygen absorption, while another assessed the efficacy of Redcivir in diagnosed patients with more severe clinical symptoms, such as the need for oxygen absorption.
According to the statement, both clinical trials, led by Chinese researchers, are being conducted in Wuhan. Gilead provides the drugs needed for the research free of charge and supports the design and development of the research. Gilead expects the lead researcher sq., which will publish more details in the near future.
Gilead further cautioned that Redcivir is an experimental drug that has so far been used by only a handful of patients infected with the new coronavirus (2019-nCoV), so the company does not know enough about its efficacy and is not sufficient to ensure that the drug is widely used. If the results of the preliminary study show the potential safety and efficacy of Redciewe’s treatment of the new coronavirus (2019-nCo0V) infection, the company will work to develop programs that will open Redciewe to more patients through appropriate channels and discuss the possibility of future clinical trials with multiple agencies.
It is understood that although it is not yet known whether the drug can safely and effectively treat the new coronavirus (2019-nCoV) infection, but in view of the urgency of the current situation, Gilead side is taking a variety of measures to speed up production progress, increase supply, including the expansion of the external network of pharmaceutical partners to speed up the procurement of raw materials, Production of API and pharmaceuticals, while Gilead began manufacturing Ridsiewe in-house to supplement the production capacity of the external production network.
Redswell has yet to go public globally. The National Health and Reform Commission expert group put forward a plan for this, apply for the green channel, and Gilead company directly began contact. Led by the Sino-Japanese Friendship Hospital, a clinical study of Redsiewe’s treatment of new coronaviruses is planned in Wuhan. On February 2, the State Drug Administration’s Drug Review Center announced that a clinical trial application for the drug Ridsiewe, a new coronavirus pneumonia, was accepted. On February 3rd, Gilead’s Redsey wee began a randomized, double-blind, controlled Phase III clinical study in China.
Jia Yahui, deputy director of the National Health and Health Commission’s Medical and Political Medicine Bureau, said that the “effective” treatment drugs seen by the public now have a long way to go from clinical practice. “In the fight against the outbreak, we have accelerated the process of operation and shortened the cycle as much as possible, in the hope that the truly effective treatment will be applied to practical clinical practice. “